Emergent BioSolutions Inc. · NYSE:EBS

Emergent BioSolutions — Merger or Acquisition (August 2015)

14 slides from Emergent BioSolutions's merger presentation, Aug 6, 2015

  1. Slide 1: Biosciences Spin-Off

    Biosciences Spin-Off August 6, 2015 Daniel J. Abdun-Nabi President and CEO

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, without limitation, statements regarding our financial guidance, statements reg

  3. Slide 3: Overview: Plan to Spin-off Biosciences Business

    Overview Plan to Spin-off Biosciences Business Board of Directors has authorized management to pursue a tax-free spin-off of the Description company’s Biosciences business into a separate, stand-alone publicly-traded company (SpinCo) Separation is expected to create two independent public companies

  4. Slide 4: Strategic Business Rationale

    Strategic Business Rationale Compelling For Both Companies & Shareholders Enables each company to:  Tailor business strategies to best address opportunities within its target market  Enhance business focus and better align resources to achieve strategic priorities  Pursue distinct capital structu

  5. Slide 5: Strategic Business Rationale: Benefits to Emergent

    Strategic Business Rationale Benefits to Emergent  Establishes Emergent as a “pure play” company, recognized as a leader in the biodefense and emerging infectious diseases fields  Enhances its financial returns/operating margins − Reduces burdens on cash flow associated with oncology R&D − Elimina

  6. Slide 6: Emergent Company Profile Post-spin

    A global specialty biopharmaceutical company focused on providing specialty products for civilian and military populations that address intentional and naturally emerging public health threats Company Profile Post-spin Medical Countermeasure Portfolio Markets Marketed Products Pipeline C B R N E Vac

  7. Slide 7: Emergent Financial Profile

    Emergent Financial Profile Enhanced Financial Performance Continued Revenue Growth Reduced Cost Structure  Organic and M&A Enhances EBITDA  Product sales  Elimination of oncology R&D  Contracts, grants and collaborations  Elimination of selling and marketing expenses  CMO revenue, including th

  8. Slide 8: Strategic Business Rationale: Benefits to SpinCo

    Strategic Business Rationale Benefits to SpinCo  Establishes SpinCo as a “pure play” biopharmaceutical company in the highly attractive field of immuno-oncology  Targets investments and operations in the development of bi-specific therapeutics using the proprietary ADAPTIR platform technology  En

  9. Slide 9: SpinCo Company Profile

    A biopharmaceutical company focused on novel oncology and SpinCo hematology therapeutics to meaningfully improve patients’ lives Company Profile Clinical Development Stage Product/Candidate Indication Pre-Clinical Marketed Phase I Phase II Phase III IXINITY Hemophilia B WinRho ITP HepaGam B HBV VARI

  10. Slide 10: SpinCo Immuno-Oncology Platform ADAPTIR

    SpinCo Immuno-Oncology Platform Technology Core to the Company ADAPTIR™ Platform at a Glance A promising, novel approach scFv for generation of immuno-therapeutics Suitable for producing immuno-therapeutics for oncology or AIID utilizing different modes of action  Redirected T-cell Cytotoxicity  T

  11. Slide 11: SpinCo Financial Profile

    SpinCo Financial Profile Capitalized to Create Value  Fixed cash contribution from Emergent of $50M-$70M  R&D investment partially offset by: – Growing contribution from IXINITY – Stable contribution from mature products: WinRho, HepaGam B, VARIZIG – Funding from existing MOR209/ES414 partnership

  12. Slide 12: Transaction Details

    Transaction Details Biosciences Business Spin-off  Tax-free distribution to Emergent shareholders of common stock of SpinCo Structure  Stock distribution ratio to be determined Timing  Transaction anticipated to be completed in mid-2016 (subject to closing conditions)  Corporate name for SpinCo

  13. Slide 13: Summary

    Summary Biosciences Business Spin-off Spin-off is expected to create two independent public companies with distinct strategic plans, growth strategies, and operational and development priorities  Enables Emergent to establish itself as a “pure play” company in the biodefense and emerging infectious

  14. Slide 14: Biosciences Spin-Off

    Biosciences Spin-Off August 6, 2015 Daniel J. Abdun-Nabi President and CEO

Emergent BioSolutions — Merger or Acquisition (August 2015) on 6ix